Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;223(3):539-542.
doi: 10.1016/j.amjsurg.2021.11.017. Epub 2021 Nov 16.

Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center

Affiliations

Factors associated with relapse-free survival after neoadjuvant chemotherapy for breast cancer at a safety net medical center

Rachel E Sargent et al. Am J Surg. 2022 Mar.

Abstract

Background: This study was designed to assess prognostic factors associated with relapse-free survival (RFS) after neoadjuvant chemotherapy (NAC) for breast cancer.

Methods: A single-institution retrospective analysis was performed including clinical, radiographic, and pathologic parameters for all breast cancer patients treated with NAC from 2015 to 2018. All patients had pre-and post-NAC MRI.

Results: For 102 patients, median follow-up was 47.4 months, and the five-year RFS was 74%. The 41 (40%) patients who achieved pathologic complete response (pCR) after NAC had a significantly higher five-year RFS than the 61 not achieving pCR. For 31 patients with triple-negative cancers, the five-year RFS was significantly higher in those achieving pCR vs. no pCR. The 44 (43%) patients who achieved radiographic complete response (rCR) after NAC had similar five-year RFS to the 58 (57%) not achieving rCR.

Conclusion: pCR, node-negativity after NAC, and triple-negative subtype were prognostic factors associated with relapse-free survival after NAC.

Keywords: Breast cancer; Complete response; Hispanic; Neoadjuvant chemotherapy.

PubMed Disclaimer

Comment in

LinkOut - more resources